Apogee Therapeutics Shares Surge Following $1.3 Billion Blackstone Financing Partnership (APOG)
Key takeaways
- Under the terms of the deal, Blackstone will receive tiered royalties in the low-to-mid single-digit range on annual worldwide sales of zumilokibart over a 15-year period.
- The synthetic royalty component of the agreement will be provided through several funding stages.
- A further $400 million would become available upon U.S.
Apogee Therapeutics Shares Surge Following $1.3 Billion Blackstone Financing Partnership (APOG) Fiona Craig Wed, May 27, 2026 at 7:06 PM GMT+7 1 min read APGE APOG medical research 17 ©This Is Engineering Shares of Apogee Therapeutics (NASDAQ:APOG) climbed roughly 16% in premarket trading on Wednesday after the biotechnology company announced a $1.3 billion financing agreement with Blackstone Life Sciences to support the development and commercial launch of zumilokibart, its treatment candidate for atopic dermatitis.
The financing arrangement includes up to $800 million in synthetic royalty funding alongside as much as $500 million in senior corporate debt financing, which will be made available subject to mutual agreement between both companies.
Under the terms of the deal, Blackstone will receive tiered royalties in the low-to-mid single-digit range on annual worldwide sales of zumilokibart over a 15-year period. However, no royalties will apply to annual global sales above $8 billion.